{"title":"Characterization of a novel α-thalassemia deletion (Dongxing deletion; --<sup>DX</sup>) by CNV-seq in a Chinese female with Hb H disease: a case report.","authors":"Youqiong Li, Ting Qin, Liang Liang, Ying Li, Lihong Zheng","doi":"10.1080/16078454.2026.2692179","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This study was initiated to resolve a discrepancy between conventional genetic findings and clinical presentation in a proband with <i>α</i>-thalassemia. The initial genotype (-α<sup>4.2</sup>/-α<sup>4.2</sup>) was inconsistent with the Hb H disease phenotype, suggesting the presence of an undetected pathogenic variant.</p><p><strong>Methods: </strong>To characterize the underlying genetic defect, we employed a multi-technique approach. The proband's DNA was analyzed using multiplex ligation-dependent probe amplification (MLPA), third-generation sequencing (TGS), and copy number variation sequencing (CNV-seq). Prenatal diagnosis was performed because the husband carried the --<sup>SEA</sup>/αα genotype.</p><p><strong>Results: </strong>Investigations revealed a novel, large deletion on the <i>α</i>-globin gene cluster. Unlike MLPA and TGS, which indicated a deletion but could not precisely define its breakpoints due to its telomeric location, CNV-seq successfully mapped the deletion to chr16:97840-230167. This represents a 132,327 bp (132 kb) deletion, which we designated the 'Dongxing' (--<sup>DX</sup>) deletion. The proband's corrected genotype was confirmed as --<sup>DX</sup>/-α<sup>4.2</sup>. Prenatal diagnosis revealed the fetus had Hb H disease (--<sup>SEA</sup>/-α<sup>4.2</sup>).</p><p><strong>Conclusions: </strong>We identified and characterized a novel <i>α</i>-thalassemia deletion (Dongxing deletion) using CNV-seq. This case highlights the limitations of conventional genotyping and underscores the importance of comprehensive genetic analysis in cases of genotype-phenotype discrepancy.</p>","PeriodicalId":13161,"journal":{"name":"Hematology","volume":"31 1","pages":"2692179"},"PeriodicalIF":2.0000,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/16078454.2026.2692179","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/6/19 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: This study was initiated to resolve a discrepancy between conventional genetic findings and clinical presentation in a proband with α-thalassemia. The initial genotype (-α4.2/-α4.2) was inconsistent with the Hb H disease phenotype, suggesting the presence of an undetected pathogenic variant.
Methods: To characterize the underlying genetic defect, we employed a multi-technique approach. The proband's DNA was analyzed using multiplex ligation-dependent probe amplification (MLPA), third-generation sequencing (TGS), and copy number variation sequencing (CNV-seq). Prenatal diagnosis was performed because the husband carried the --SEA/αα genotype.
Results: Investigations revealed a novel, large deletion on the α-globin gene cluster. Unlike MLPA and TGS, which indicated a deletion but could not precisely define its breakpoints due to its telomeric location, CNV-seq successfully mapped the deletion to chr16:97840-230167. This represents a 132,327 bp (132 kb) deletion, which we designated the 'Dongxing' (--DX) deletion. The proband's corrected genotype was confirmed as --DX/-α4.2. Prenatal diagnosis revealed the fetus had Hb H disease (--SEA/-α4.2).
Conclusions: We identified and characterized a novel α-thalassemia deletion (Dongxing deletion) using CNV-seq. This case highlights the limitations of conventional genotyping and underscores the importance of comprehensive genetic analysis in cases of genotype-phenotype discrepancy.
期刊介绍:
Hematology is an international journal publishing original and review articles in the field of general hematology, including oncology, pathology, biology, clinical research and epidemiology. Of the fixed sections, annotations are accepted on any general or scientific field: technical annotations covering current laboratory practice in general hematology, blood transfusion and clinical trials, and current clinical practice reviews the consensus driven areas of care and management.